GlaxoSmithKline plc Stumbles But It’s Still A Buy

Drug setbacks highlight GlaxoSmithKline plc’s (LON:GSK) robustness

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Drug-maker GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has announced its third setback in almost as many days with news of failed drugs trials. The shares are down 3% since the start of the week.  But that’s quite a muted response to three disappointments in GSK’s late-stage pipeline, which to my mind demonstrates the company’s robustness. I doubt rival AstraZeneca (LSE: AZN) (NYSE: AZN.US) could meet a triple failure with such equanimity.

Bad news comes in threes

On Wednesday GSK announced it had halted the last-stage trials of lung-cancer vaccine MAGE-A3. On Monday it withdrew an application for approval of an ovarian cancer drug called Votrient after disappointing Phase III studies. The day before it had released details of its unsuccessful trials of heart disease therapy darapladib.

gskThis is not the end of the road for these drugs: trials will continue on their efficacy in different clinical situations. But it is a significant setback in GSK’s pipeline. GSK acquired darapladib with its $3bn acquisition of US biotech firm Human Genome Sciences in 2012 and it was considered one of its leading prospects. MAGE-A3 is an immunotherapy treatment which stimulates the body’s own immune system to treat cancer.  It’s a field where GSK has been lagging — and still is.

People attach significance to events that come in threes: buses, accidents, bad news, profit warnings, whatever. Perhaps it’s because two things happening together isn’t unusual – just a ‘coincidence’ – whilst the laws of randomness make four events a rarer occurrence. My hunch is that similar triple disappointments at Astra would have sent its stock plunging on talk of its business model failing. AstraZeneca’s share price is supported by faith in the company delivering on its ambitious pipeline, a balloon that could easily burst.

Less risky than Astra

That, in a nutshell, is why I hold GSK but no longer hold Astra. GSK has lower downside risk. It has largely overcome the patent cliff. Turnover has stabilised, with two new asthma and respiratory drugs hopefully replacing sales from the company’s blockbuster product Advair. In contrast even Astra’s own CEO doesn’t expect to see sales recovering until 2017: the longer time frame means more uncertainty.

GSK also has two business lines less susceptible to the uncertainties of scientific discovery. Conventional vaccines and consumer healthcare, such as over-the-counter medicines, make up a third of turnover.

GSK has the largest vaccines business in the world, and whilst it’s managed alongside the pharmaceuticals business it doesn’t require the same massive upfront R&D investment. The consumer healthcare market is driven by ageing populations in the developed world and increasing wealth in emerging markets, just like the pharmaceuticals business is. But its characteristics are more like a consumer goods company than a drugs company.

Cheaper than Astra

Remarkably, in the light of its lower risk, GSK is actually now cheaper than Astra: on a forward PE of 14.4 against 15.3, and yielding 4.9% against 4.5%. It could be a good time to prescribe a dose of GSK shares to inoculate against pension poverty!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tony owns shares in GSK but no other shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

 

More on Investing Articles

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

Buying 8,617 Legal & General shares would give me a stunning income of £1,840 a year

Legal & General shares offer one of the highest dividend yields on the entire FTSE 100. Harvey Jones wants to…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

£25k to invest? Here’s how I’d try to turn that into a second income of £12,578 a year!

If Harvey Jones had a lump sum to invest today he'd go flat out buying top FTSE 100 second income…

Read more »

Union Jack flag in a castle shaped sandcastle on a beautiful beach in brilliant sunshine
Investing Articles

2 lesser-known dividend stocks to consider this summer

Summer is here and global markets could be heading for a period of subdued trading. But our writer thinks there…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Here’s how I’d aim to build a £50K SIPP into a £250K retirement fund

Our writer outlines the approach he would take to try and increase the value of his SIPP multiple times in…

Read more »

Investing Articles

9.4%+ yields! 3 proven FTSE 100 dividend payers I’d buy for my Stocks and Shares ISA

Our writer highlights a trio of FTSE 100 shares with yields close to 10%. He'd happily pop them into his…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

Are Raspberry Pi shares a once-in-a-lifetime chance to get rich?

With Raspberry Pi shares surging after a successful IPO, could this UK tech startup offer a long-term wealth creation opportunity…

Read more »

Newspaper and direction sign with investment options
Investing Articles

Huge gains and 9% yields: why now’s an amazing time to be a stock market investor

The stock market’s generating fantastic returns in 2024. Whether you're looking for gains or income, it’s a great time to…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

This steady dividend payer looks like one of the best bargain stocks in the FTSE 100

A yield of 4.7% and a consistent dividend record make this FTSE 100 company look like good value in an…

Read more »